Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.

ABSTRACT:

Introduction

Surgery in people with haemophilia and factor VIII inhibitors is typically managed with perioperative administration of haemostatic agents to prevent or control the occurrence of bleeding events. Practical experience of surgery in patients with inhibitors who are receiving treatment with emicizumab is growing; however, the novelty of the situation means that standardised guidelines are lacking with regard to the concomitant administration of haemostatic agents, including dose and laboratory monitoring.

Aim

To review approaches to haemostatic management during major and minor invasive procedures in patients with haemophilia A and inhibitors, and to provide recommendations for controlling bleeding events.

Methods

A search was conducted, limited to the past

SUBMITTER: Jimenez-Yuste V 

PROVIDER: S-EPMC8359827 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature